Psoriasis Clinical Trial

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Summary

Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).

View Full Description

Full Description

NOTE: Detailed Description : data not entered

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient must have participated in core study CAIN457F2304, and must have completed the entire treatment period up to and including Week 104.
Patients must be deemed by the investigator to benefit from continued secukinumab therapy.

Exclusion Criteria:

Plans for administration of live vaccines during the extension study period.
Any patient taking other concomitant biologic immunomodulating agent(s) except secukinumab.
Any patient who is deemed not to be benefiting from the study treatment based upon lack of improvement or worsening of their symptoms.

All other protocol related inclusion/exclusion criteria will apply.

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

55

Study ID:

NCT03769168

Recruitment Status:

Active, not recruiting

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 23 Locations for this study

See Locations Near You

St Lukes Intermountain Research Center
Boise Idaho, 83702, United States
Cincinnati Childrens Hospital Division of Rheumatology
Cincinnati Ohio, 45229, United States
Legacy Emanuel Research Hospital Portland Randall Childrens Hospital
Portland Oregon, 97232, United States
Novartis Investigative Site
Bruxelles , 1200, Belgium
Novartis Investigative Site
Gent , 9000, Belgium
Novartis Investigative Site
Freiburg , 79106, Germany
Novartis Investigative Site
Hamburg , 22081, Germany
Novartis Investigative Site
Saint Augustin , 53757, Germany
Novartis Investigative Site
Genova GE, 16147, Italy
Novartis Investigative Site
Napoli , 80131, Italy
Novartis Investigative Site
Krakow , 31503, Poland
Novartis Investigative Site
Ekaterinburg , 62014, Russian Federation
Novartis Investigative Site
Moscow , 11999, Russian Federation
Novartis Investigative Site
Saint-Petersburg , 19410, Russian Federation
Novartis Investigative Site
Voronezh , 39403, Russian Federation
Novartis Investigative Site
Panorama Western Cape, 7500, South Africa
Novartis Investigative Site
Cape Town , 7925, South Africa
Novartis Investigative Site
Santiago De Compostela Galicia, 15706, Spain
Novartis Investigative Site
Valencia , 46026, Spain
Novartis Investigative Site
Istanbul Halkali, 34303, Turkey
Novartis Investigative Site
Istanbul TUR, 34098, Turkey
Novartis Investigative Site
Ankara , 06100, Turkey
Novartis Investigative Site
Istanbul , 34390, Turkey

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

55

Study ID:

NCT03769168

Recruitment Status:

Active, not recruiting

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.